[{"id":"a4247f5e-b84a-4f2b-a095-1fca8e76f331","acronym":"","url":"https://clinicaltrials.gov/study/NCT06905509","created_at":"2025-08-02T14:06:01.421Z","updated_at":"2025-08-02T14:06:01.421Z","phase":"Phase 2","brief_title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","source_id_and_acronym":"NCT06905509","lead_sponsor":"University of California, Davis","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 08/01/2030","study_completion_date":" 08/01/2030","last_update_posted":"2025-04-01"},{"id":"796304d3-46d7-4eb0-aa64-9c9bbe7b7955","acronym":"Pola-R-ICE","url":"https://clinicaltrials.gov/study/NCT04833114","created_at":"2021-04-06T11:55:24.930Z","updated_at":"2025-02-25T14:15:54.989Z","phase":"Phase 3","brief_title":"Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT04833114 - Pola-R-ICE","lead_sponsor":"GWT-TUD GmbH","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 306","initiation":"Initiation: 04/30/2021","start_date":" 04/30/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-18"},{"id":"90ac22c8-dcce-478e-af97-ed4ef0a3b357","acronym":"","url":"https://clinicaltrials.gov/study/NCT04665765","created_at":"2021-01-19T20:43:36.698Z","updated_at":"2025-02-25T14:08:04.780Z","phase":"Phase 2","brief_title":"Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04665765","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 01/18/2021","start_date":" 01/18/2021","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/08/2025","study_completion_date":" 07/08/2025","last_update_posted":"2025-02-17"},{"id":"4448c756-db79-4484-aae6-303e6174097b","acronym":"AALL1631","url":"https://clinicaltrials.gov/study/NCT03007147","created_at":"2021-01-18T14:47:39.557Z","updated_at":"2025-02-25T14:50:25.163Z","phase":"Phase 3","brief_title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03007147 - AALL1631","lead_sponsor":"Children's Oncology Group","biomarkers":" ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R","pipe":" | ","alterations":" BCR-ABL1 fusion • ABL1 fusion","tags":["ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexrazoxane • levoleucovorin calcium • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 475","initiation":"Initiation: 08/08/2017","start_date":" 08/08/2017","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-13"},{"id":"99c4032a-3714-4351-a6af-2208fcba233e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684368","created_at":"2021-01-19T20:47:18.675Z","updated_at":"2025-02-25T15:11:50.245Z","phase":"Phase 2","brief_title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","source_id_and_acronym":"NCT04684368","lead_sponsor":"Children's Oncology Group","biomarkers":" NF1","pipe":" | ","alterations":" AFP elevation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cyclophosphamide • ifosfamide • etoposide IV • mesna • thiotepa • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 07/13/2021","start_date":" 07/13/2021","primary_txt":" Primary completion: 12/21/2029","primary_completion_date":" 12/21/2029","study_txt":" Completion: 12/21/2029","study_completion_date":" 12/21/2029","last_update_posted":"2025-02-13"},{"id":"a5031666-4a50-4613-ab67-b57e264769e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04322318","created_at":"2023-11-21T20:16:14.157Z","updated_at":"2025-02-25T15:11:30.447Z","phase":"Phase 2","brief_title":"A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT","source_id_and_acronym":"NCT04322318","lead_sponsor":"Children's Oncology Group","biomarkers":" TP53","pipe":"","alterations":" ","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 221","initiation":"Initiation: 10/19/2020","start_date":" 10/19/2020","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-02-13"},{"id":"dba621d0-4a3a-4b6c-9b33-c48c7ade782a","acronym":"iMATRIX GLO","url":"https://clinicaltrials.gov/study/NCT05533775","created_at":"2022-09-09T15:55:02.207Z","updated_at":"2025-02-25T15:27:37.954Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05533775 - iMATRIX GLO","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 03/30/2027","primary_completion_date":" 03/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2025-02-10"},{"id":"5416351c-6e6b-41af-9e81-7fd2a0e36c13","acronym":"GETUG 13","url":"https://clinicaltrials.gov/study/NCT00104676","created_at":"2021-01-18T00:20:19.559Z","updated_at":"2025-02-25T16:35:55.671Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors","source_id_and_acronym":"NCT00104676 - GETUG 13","lead_sponsor":"UNICANCER","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • ifosfamide • oxaliplatin • etoposide IV • bleomycin"],"overall_status":"Completed","enrollment":" Enrollment 263","initiation":"Initiation: 11/26/2003","start_date":" 11/26/2003","primary_txt":" Primary completion: 03/29/2012","primary_completion_date":" 03/29/2012","study_txt":" Completion: 02/08/2023","study_completion_date":" 02/08/2023","last_update_posted":"2025-02-06"},{"id":"7114fae7-0419-4c0e-a010-ae5f4d1c710b","acronym":"AEWS1221","url":"https://clinicaltrials.gov/study/NCT02306161","created_at":"2023-11-28T02:14:27.984Z","updated_at":"2025-02-25T16:36:29.981Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","source_id_and_acronym":"NCT02306161 - AEWS1221","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • daunorubicin • ganitumab (AMG 479)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 312","initiation":"Initiation: 12/12/2014","start_date":" 12/12/2014","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 09/19/2025","study_completion_date":" 09/19/2025","last_update_posted":"2025-02-06"},{"id":"33da474f-b112-4a34-ad2b-bf3aa8c54e06","acronym":"AALL1231","url":"https://clinicaltrials.gov/study/NCT02112916","created_at":"2021-01-18T09:46:35.591Z","updated_at":"2025-02-25T16:51:23.270Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT02112916 - AALL1231","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 847","initiation":"Initiation: 10/04/2014","start_date":" 10/04/2014","primary_txt":" Primary completion: 03/31/2020","primary_completion_date":" 03/31/2020","study_txt":" Completion: 09/18/2025","study_completion_date":" 09/18/2025","last_update_posted":"2025-02-04"},{"id":"ea7e7be5-dd5d-4509-9884-da4eb277aa63","acronym":"P+R-ICE","url":"https://clinicaltrials.gov/study/NCT05221645","created_at":"2022-02-05T18:29:06.759Z","updated_at":"2025-02-25T16:17:16.628Z","phase":"Phase 2","brief_title":"Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT05221645 - P+R-ICE","lead_sponsor":"University of Southampton","biomarkers":" CD20","pipe":" | ","alterations":" CD34 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Rituxan (rituximab) • cytarabine • ifosfamide • etoposide IV • carmustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 06/27/2022","start_date":" 06/27/2022","primary_txt":" Primary completion: 05/30/2026","primary_completion_date":" 05/30/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-12-05"},{"id":"c9384ff3-1b2b-4e9a-9109-2fbfa2d899c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05364424","created_at":"2022-05-06T18:55:12.445Z","updated_at":"2024-07-02T16:34:26.387Z","phase":"Phase 1","brief_title":"A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma","source_id_and_acronym":"NCT05364424","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/04/2022","start_date":" 11/04/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-13"},{"id":"576b9aae-2746-4ca3-a5a4-167bcd5465e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06393361","created_at":"2024-05-04T04:28:35.114Z","updated_at":"2024-07-02T16:34:27.321Z","phase":"Phase 2","brief_title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.","source_id_and_acronym":"NCT06393361","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • ifosfamide • etoposide IV • decitabine • pegylated liposomal doxorubicin • Adcetris (brentuximab vedotin) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-11"},{"id":"c2c40e25-bf03-4412-bf0e-9712fe410547","acronym":"","url":"https://clinicaltrials.gov/study/NCT04947501","created_at":"2021-07-01T14:54:45.053Z","updated_at":"2024-07-02T16:34:27.282Z","phase":"Phase 1","brief_title":"A Study of N9 Chemotherapy in Children With Neuroblastoma","source_id_and_acronym":"NCT04947501","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • topotecan • mesna • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 06/22/2025","primary_completion_date":" 06/22/2025","study_txt":" Completion: 06/22/2025","study_completion_date":" 06/22/2025","last_update_posted":"2024-06-11"},{"id":"261358fc-b7b1-46b5-8898-75ce2caa34b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04224337","created_at":"2024-06-01T04:11:07.379Z","updated_at":"2024-07-02T16:34:59.784Z","phase":"Phase 2","brief_title":"Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma","source_id_and_acronym":"NCT04224337","lead_sponsor":"Seoul National University Hospital","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • doxorubicin hydrochloride • ifosfamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 06/11/2020","start_date":" 06/11/2020","primary_txt":" Primary completion: 08/14/2023","primary_completion_date":" 08/14/2023","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-05-31"},{"id":"89d85ce4-ea03-4058-ba7a-82fb284611ca","acronym":"EPCORE NHL-2","url":"https://clinicaltrials.gov/study/NCT04663347","created_at":"2021-06-15T19:53:31.777Z","updated_at":"2024-07-02T16:34:59.645Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","source_id_and_acronym":"NCT04663347 - EPCORE NHL-2","lead_sponsor":"Genmab","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • lenalidomide • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • vincristine • prednisone • dexamethasone • bendamustine • Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 662","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 03/31/2029","primary_completion_date":" 03/31/2029","study_txt":" Completion: 03/31/2029","study_completion_date":" 03/31/2029","last_update_posted":"2024-05-31"},{"id":"1d61c822-8b23-4a8f-b429-8c238d66ec51","acronym":"HR-NBL2","url":"https://clinicaltrials.gov/study/NCT04221035","created_at":"2021-01-18T20:32:43.345Z","updated_at":"2024-07-02T16:35:03.584Z","phase":"Phase 3","brief_title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","source_id_and_acronym":"NCT04221035 - HR-NBL2","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" MYCN • MYCL","pipe":" | ","alterations":" MYCN amplification • MYCL amplification","tags":["MYCN • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dacarbazine • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • cyclophosphamide intravenous • vindesine"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 11/05/2019","start_date":" 11/05/2019","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2032","study_completion_date":" 11/01/2032","last_update_posted":"2024-05-15"},{"id":"970ea094-a661-4898-85eb-a557dddaf167","acronym":"","url":"https://clinicaltrials.gov/study/NCT01979536","created_at":"2021-01-18T09:00:59.609Z","updated_at":"2024-07-02T16:35:06.864Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma","source_id_and_acronym":"NCT01979536","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • Adcetris (brentuximab vedotin) • dexamethasone • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 137","initiation":"Initiation: 11/13/2013","start_date":" 11/13/2013","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2024-04-30"},{"id":"89dd2a7f-11f6-4dd3-813c-39c7d1f75e4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01602666","created_at":"2021-01-18T06:51:17.342Z","updated_at":"2024-07-02T16:35:08.661Z","phase":"Phase 2","brief_title":"Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors","source_id_and_acronym":"NCT01602666","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cyclophosphamide • ifosfamide • etoposide IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 262","initiation":"Initiation: 06/27/2012","start_date":" 06/27/2012","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-19"},{"id":"ec361a88-10be-462e-b8c7-8fa193d6a067","acronym":"","url":"https://clinicaltrials.gov/study/NCT03418038","created_at":"2021-01-18T16:51:47.082Z","updated_at":"2024-07-02T16:35:11.929Z","phase":"Phase 2","brief_title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT03418038","lead_sponsor":"Mayo Clinic","biomarkers":" IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation","tags":["IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-02"},{"id":"00bbb33d-25be-4970-828c-31b893d1860f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03440567","created_at":"2021-01-18T16:58:12.301Z","updated_at":"2024-07-02T16:35:12.336Z","phase":"Phase 1","brief_title":"Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma","source_id_and_acronym":"NCT03440567","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20 • CCND1","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imbruvica (ibrutinib) • Rituxan (rituximab) • Bavencio (avelumab) • cyclophosphamide • ifosfamide • etoposide IV • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • utomilumab (PF-05082566) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 04/02/2018","start_date":" 04/02/2018","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-03-29"},{"id":"365bcd51-2ab8-4615-b16d-85cc815ed781","acronym":"","url":"https://clinicaltrials.gov/study/NCT01505569","created_at":"2021-01-18T06:19:27.289Z","updated_at":"2025-02-25T14:00:01.019Z","phase":"","brief_title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","source_id_and_acronym":"NCT01505569","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" MYCN • CD34","pipe":" | ","alterations":" LDH elevation • MYCN expression","tags":["MYCN • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation • MYCN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • ifosfamide • etoposide IV • melphalan • mesna • thiotepa • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 10/20/2011","start_date":" 10/20/2011","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2024-02-26"},{"id":"48c8c685-3b55-4785-bf23-1b310216477e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02227199","created_at":"2021-01-18T10:26:38.286Z","updated_at":"2024-07-02T16:35:19.256Z","phase":"Phase 1/2","brief_title":"Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT02227199","lead_sponsor":"University of Washington","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cyclophosphamide • ifosfamide • etoposide IV • Adcetris (brentuximab vedotin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 10/10/2014","start_date":" 10/10/2014","primary_txt":" Primary completion: 03/30/2020","primary_completion_date":" 03/30/2020","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-02-15"},{"id":"53124618-2267-481b-8fe0-bf52fc60b679","acronym":"","url":"https://clinicaltrials.gov/study/NCT00936936","created_at":"2021-01-18T03:38:02.528Z","updated_at":"2024-07-02T16:35:20.708Z","phase":"Phase 2","brief_title":"High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors","source_id_and_acronym":"NCT00936936","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • docetaxel • ifosfamide • etoposide IV • melphalan • mesna"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 06/02/2009","start_date":" 06/02/2009","primary_txt":" Primary completion: 01/11/2024","primary_completion_date":" 01/11/2024","study_txt":" Completion: 01/11/2024","study_completion_date":" 01/11/2024","last_update_posted":"2024-02-06"}]